U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.